Clinical Trial Update: Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer [Phase 2]

View source ↗

Summary

Phase II clinical trial of peptide receptor radionuclide therapy in combination with immunotherapy for Merkel cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• Peptide Receptor Radionuclide Therapy

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Merkel Cell Carcinoma | Phase 2 | Status: RECRUITING